Cyxone AB

ACTIVE

Hyllie Boulevard 34, Malmö, Skåne, Swedenwww.cyxone.comPublic3 employeesEstablished: 2015-01-01

Clinical Trials

5 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2015

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

83.3%

Trial Status Distribution

Active, not recruiting

83.3%

Completed

16.7%

Clinical Trials

Trials sponsored by this organization (6)

A study to evaluate the possible side and the efficacy of orally administered Rabeximod when taken in combination with methotrexate compared with Methotrexate only in patients with active, moderate to severe rheumatoid arthritis with inadequate response to methotrexate

Phase 1

Active, not recruiting

interventional

Aug 2022160 participants

A study to evaluate the possible side and the efficacy of orally administered Rabeximod when taken in combination with methotrexate compared with Methotrexate only in patients with active, moderate to severe rheumatoid arthritis with inadequate response to methotrexate

Phase 1

Active, not recruiting

interventional

Jun 2022160 participants

A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19)

Phase 1

Active, not recruiting

Mar 2021300 participants

A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19)

Phase 1

Active, not recruiting

Dec 2020300 participants

A study to learn how well the drug Rabeximod works and how safe Rabeximod is in people who have Moderate Coronavirus Disease (COVID-19)

Phase 1

Active, not recruiting

Nov 2020300 participants

Phase I, Single-Center, Randomized, Placebo-Controlled, Double-Blinded Study with Single Ascending Doses, Evaluating the Safety and Tolerability of T20K, Administered by a 1-hr IV Infusion in Healthy Male Volunteers

Completed

interventional

40 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations